New Strong Buy Stocks for July 9th
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Zacks Investment Research7/9/2026Positive
PTGX
Protagonist Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.86B
P/E Ratio
—
EPS
$-1.80
Beta
1.79
52W High
$141.08
52W Low
$50.48
50-Day MA
$106.99
200-Day MA
$91.14
Dividend Yield
—
Profit Margin
-154.90%
Forward P/E
27.93
PEG Ratio
0.00
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Fundamentals
| Revenue (TTM) | $74.06M |
| Gross Profit (TTM) | $74.06M |
| EBITDA | $-141.02M |
| Operating Margin | -6.47% |
| Return on Equity | -17.10% |
| Return on Assets | -12.40% |
| Revenue/Share (TTM) | $1.16 |
| Book Value | $10.21 |
| Price-to-Book | 12.92 |
| Price-to-Sales (TTM) | 119.60 |
| EV/Revenue | 107.12 |
| EV/EBITDA | 244.64 |
| Quarterly Earnings Growth (YoY) | 351.30% |
| Quarterly Revenue Growth (YoY) | 99.00% |
| Shares Outstanding | $64.31M |
| Float | $52.49M |
| % Insiders | 0.71% |
| % Institutions | 125.29% |
Historical Volatility
HV 10-Day
40.51%
HV 20-Day
39.94%
HV 30-Day
48.45%
HV 60-Day
46.70%
HV Rank
77.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($120.54 target)
3
Strong Buy9
Buy1
HoldLatest News
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research7/8/2026Positive
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Zacks Investment Research7/7/2026Positive
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Accesswire7/1/2026Neutral
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Accesswire6/16/2026Neutral
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha6/10/2026Neutral
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.
Accesswire6/1/2026Neutral
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Accesswire5/28/2026Neutral
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Zacks Investment Research5/22/2026Neutral
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
Zacks Investment Research5/12/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026